John Kowalski Net Worth

The estimated Net Worth of John M Kowalski is at least $50.2 millier dollars as of 19 March 2020. Mr. Kowalski owns over 3,000 units of Biosig Technologies Inc stock worth over $50,176 and over the last 5 years he sold BSGM stock worth over $0. In addition, he makes $0 as Vice President - Sales at Biosig Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kowalski BSGM stock SEC Form 4 insiders trading

John has made over 2 trades of the Biosig Technologies Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of BSGM stock worth $8,940 on 19 March 2020.

The largest trade he's ever made was buying 3,000 units of Biosig Technologies Inc stock on 19 March 2020 worth over $8,940. On average, John trades about 2,500 units every 2 days since 2020. As of 19 March 2020 he still owns at least 112,000 units of Biosig Technologies Inc stock.

You can see the complete history of Mr. Kowalski stock trades at the bottom of the page.

John Kowalski biography

John M. Kowalski serves as Vice President - Sales of the Company. Mr. Kowalski brings to the Company over 30 years of experience in medical device sales, including over 20 years at Biosense Webster, a Johnson & Johnson company. Most recently, he served as Northeast Area Director, a role, in which he was responsible for leading six high-performing cardiac electrophysiology catheter and equipment market sales teams, consisting of 140 sales and clinical support employees. Mr. Kowalski helped drive $175M of disposables and system sales and has consistently exceeded area sales objectives. Having led U.S. strategic planning teams in his previous roles, Mr. Kowalski brings to BioSig proven track record in identifying key business growth opportunities within the cardiac electrophysiology market. Mr. Kowalski is a holder of numerous Biosense Webster leadership awards, including a record 18-year Founders Club Award, and several “Area and Region of the Year” awards.

What's John Kowalski's mailing address?

John's mailing address filed with the SEC is C/O BIOSIG TECHNOLOGIES, INC., 54 WILTON ROAD, 2ND FLOOR, WESTPORT, CT, 06880.

Insiders trading at Biosig Technologies Inc

Over the last 9 years, insiders at Biosig Technologies Inc have traded over $1,778,587 worth of Biosig Technologies Inc stock and bought 1,345,515 units worth $2,296,289 . The most active insiders traders include Kenneth L Londoner, Asher Holzer et Jerome B Zeldis. On average, Biosig Technologies Inc executives and independent directors trade stock every 24 days with the average trade being worth of $11,433. The most recent stock trade was executed by Kenneth L Londoner on 13 June 2023, trading 15,600 units of BSGM stock currently worth $19,344.

What does Biosig Technologies Inc do?

biosig technologies, inc. (otcqb: bsgm) is a medical device company that is developing a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (ep) marketplace. led by a proven management team and a veteran, independent board of directors, minneapolis-based biosig is preparing to commercialize its pure ep system.

Complete history of Mr. Kowalski stock trades at Biosig Technologies Inc

Biosig Technologies Inc executives and stock owners

Biosig Technologies Inc executives and other stock owners filed with the SEC include:

• Kenneth Londoner,
  Executive Chairman of the Board, Chief Executive Officer
• Steven Chaussy,
  Chief Financial Officer
• Kenneth L. Londoner M.B.A., MBA,
  Founder, CEO & Exec. Chairman
• Samuel Navarro,
  Independent Director
• Jeffrey O'Donnell,
  Lead Independent Director
• Martha Pease,
  Independent Director
• Andrew Filler,
  Independent Director
• David Weild,
  Independent Director
• Patrick Gallagher,
  Independent Director
• Donald Foley,
  Independent Director
• Anthony Zook,
  Director
• Manasi Patwardhan,
  Director of Strategic Planning
• Olivier Chaudoir,
  Senior Director of Marketing
• Julie Stephenson,
  Vice President - Clinical Affairs, Senior Director of Clinical Affairs
• Andrew Ballou,
  Vice President - Investor Relations
• John Kowalski,
  Vice President - Sales
• John Sieckhaus,
  Chief Operating Officer
• Gray Fleming,
  Chief Commercial Officer
• Steven Chaussy,
  Chief Financial Officer
• Natasha Drapeau,
  Exec. VP
• Brenda Castrodad,
  Director of HR
• Lora Mikolaitis,
  VP of Admin.
• Dr. Budimir S. Drakulic Ph.D.,
  Chief Scientist
• Steven Eric Abelman,
  Director
• Steve Chaussy,
  Chief Financial Officer
• Roy T Tanaka,
  Director
• Lora Mikolaitis,
  10% owner
• Seth H. Z. Fischer,
  Director
• Joseph Rafferty,
  Chief Commercialization Offcr
• Jerome B Zeldis,
  Director
• Asher Holzer,
  Director
• Gregory D Cash,
  President and CEO
• James L Klein,
  Director
• James J Barry,
  Director
• John Sieckhaus,
  Chief Operating Officer
• Gray Fleming,
  Chief Commercial Officer
• Steven J Buhaly,
  Chief Financial Officer
• Frederick Hrkac,
  Director
• Donald Browne,
  Director
• Christopher Allen Baer,
  Director